Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR) reported Q1 2026 results and a clinical update on May 7, 2026. Key highlights: aleniglipron Phase 2 ACCESS II showed placebo-adjusted weight loss up to 16.3% at 44 weeks; the company received positive end-of-Phase 2 FDA feedback and plans Phase 3 initiation in Q3 2026. Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026, projected to fund operations through end of 2028.
AI-generated analysis. Not financial advice.
Positive
- Placebo-adjusted weight loss up to 16.3% at 44 weeks
- Positive end-of-Phase 2 FDA feedback enabling Phase 3 plan
- Cash position of $1.5 billion through March 31, 2026
- Phase 3 initiation for aleniglipron targeted in Q3 2026
- Multiple ADA presentations scheduled June 5–8, 2026
Negative
- Q1 2026 net loss of $76.0 million
- R&D expenses increased to $66.5 million in Q1 2026
- G&A expenses increased to $22.9 million in Q1 2026
Key Figures
Market Reality Check
Peers on Argus
GPCR slipped 0.63% while peers were mixed: ELVN -1.85%, AMLX -2.97%, but NUVB +1.31% and PGEN +2.56%. This points to stock-specific dynamics rather than a uniform biotech move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings and update | Positive | -2.7% | Q4 2025 results, positive Phase 2 aleniglipron data, $1.4B cash runway to 2028. |
| Nov 06 | Earnings and update | Positive | -1.9% | Q3 2025 results, cash of $799.0M, continued aleniglipron and amylin pipeline progress. |
| Aug 06 | Earnings and update | Positive | -0.7% | Q2 2025 results with $786.5M cash and expanding obesity clinical program. |
| May 08 | Earnings and update | Positive | -4.7% | Q1 2025 results; two Phase 2b aleniglipron studies fully enrolled and strong cash base. |
| Feb 27 | Earnings and update | Positive | +4.1% | FY 2024 results; completion of ACCESS enrollment and $883.5M cash to fund R&D. |
Earnings updates with positive clinical and cash runway commentary have historically been met with modestly negative price reactions (average move -1.17%).
Across recent earnings events, GPCR has repeatedly highlighted progress for oral GLP‑1 agonist aleniglipron and oral amylin candidate ACCG‑2671, while maintaining substantial cash balances (from $786.5M to $1.4B and beyond). These updates often paired advancing trial timelines with multi‑year cash runway guidance. Despite this, shares typically moved slightly lower around earnings. Today’s Q1 2026 report continues that pattern of strong obesity pipeline development and extended runway through 2028.
Historical Comparison
In the past year, GPCR reported 5 earnings updates with an average move of -1.17%, often despite upbeat obesity pipeline and cash runway commentary, so muted or cautious reactions have been common.
Earnings releases have charted GPCR’s progression from enrolling and reporting Phase 2 aleniglipron data to preparing Phase 3, while cash grew from $799.0M to over $1.4B and now $1.5B, consistently supporting multi‑year development plans.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration filed on 2025-08-06 and valid until 2028-08-06. No usage is recorded in the provided data, but the shelf structure allows potential future capital raises without a new base registration.
Market Pulse Summary
This announcement combines Q1 2026 financials with substantial clinical milestones for obesity. Aleniglipron delivered placebo-adjusted weight loss up to 16.3% at 44 weeks and is on track for Phase 3 initiation in Q3 2026, while cash of $1.5 billion is expected to fund operations through 2028. Prior earnings reports showed a similar mix of pipeline progress and rising R&D. Investors may watch upcoming ACCESS OLE, body composition, and diabetes/obesity readouts, plus how management uses its effective S-3ASR shelf.
Key Terms
glp-1ra medical
glp-1 receptor agonist medical
amylin receptor agonist medical
single ascending dose (sad) medical
multiple ascending dose (mad) medical
open label extension (ole) medical
AI-generated analysis. Not financial advice.
Reported positive results from aleniglipron Phase 2 ACCESS II study
with up to
at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs
Data from ACCESS OLE expected in Q3 2026;
Data from the Body Composition and Type 2 Diabetes/Obesity data expected in Q4 2026
Positive end-of-Phase 2 feedback received from FDA;
aleniglipron Phase 3 initiation on track for Q3 2026
Initial data from Phase 1 single ascending dose (SAD) study of
oral small molecule amylin receptor agonist ACCG-2671 and
initiation of multiple ascending dose (MAD) study expected in Q3 2026;
Phase 1 initiation of second oral amylin candidate ACCG-3535 expected in Q4 2026
Aleniglipron, amylin and combination data to be presented
at the American Diabetes Association (ADA) 86th Scientific Sessions in June 2026
Cash, cash equivalents and short-term investments of
SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
“With positive end of Phase 2 feedback received from the FDA for aleniglipron, we are well positioned to start our Phase 3 registrational program for chronic weight management in the third quarter,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “We are also looking forward to our aleniglipron presentation along with presentations on our oral amylin and GLP-1 combination program at the upcoming ADA meeting. With our Phase 1 clinical data for our oral amylin candidate ACCG-2671 anticipated in the third quarter and additional aleniglipron data later this year, our broad portfolio positions us well in the evolving landscape that we believe will favor more accessible oral small molecules, extended maintenance treatment, and fixed dose oral combinations for specific patient populations and expanded indications.”
Recent and Upcoming Milestones
Aleniglipron - Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight
In March 2026, the Company reported data from the aleniglipron clinical program included 44-week topline data from the Phase 2 ACCESS II study, as well as interim data from body composition study and Phase 2b ACCESS open label extension (OLE) study.
- The Phase 2 ACCESS II study demonstrated a placebo-adjusted mean weight loss of
16.3% (39 Ibs; p<0.0001) at the 180 mg dose and16.0% (37 Ibs; p<0.0001) at the 240 mg dose at 44 weeks. - The ongoing ACCESS OLE study achieved continued weight loss up to
16.2% (40.5 lbs) observed with 120 mg dose at 56 weeks. - No weight loss plateau was observed in any of the studies.
Data from the ACCESS, ACCESS II, Body Composition, and the ACCESS OLE studies provide a strong foundation for the decision to advance aleniglipron into Phase 3 clinical development. The Company expects to report topline results from the ACCESS OLE and Body Composition studies in Q3 and Q4 2026, respectively.
The Company received positive end-of-Phase 2 feedback from the U.S. Food and Drug Administration (FDA) and clear guidance on the Phase 3 program with a starting titration dose of 2.5 mg and the intent to evaluate multiple doses. The Company anticipates initiating the Phase 3 program in Q3 2026.
The Company is also conducting supplementary studies to enhance the competitive profile of aleniglipron, including:
- Ongoing study of ACCESS OLE to evaluate the tolerability profile of the dosing regimen starting at the 2.5 mg dose for those previously on placebo and to collect up to 72 weeks of data exposure to aleniglipron, including 180 mg dose. Data are expected in Q3 2026.
- Ongoing Body Composition study to assess the effect of aleniglipron on body fat loss over a 44-week evaluation period, which includes a 28-week titration period and a starting dose of 2.5 mg and target dose of 180 mg of aleniglipron. These data will be used to inform the size of a sub study into the Phase 3 program. Data are expected in Q4 2026.
- Ongoing 30-week study in patients with type 2 diabetes mellitus (T2DM) with obesity/overweight and a starting dose of 2.5 mg and target dose of 180 mg of aleniglipron to evaluate the potential for including participants with T2DM in the Phase 3 obesity program. Data are expected in Q4 2026.
- Ongoing SWITCH study to assess the transition or switching from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance. This study assesses different aleniglipron starting doses and weight loss maintenance over 12 weeks. Data are expected in Q4 2026.
Oral Small Molecule Amylin Receptor Agonists
- In December 2025, the Company advanced ACCG-2671 into a Phase 1 clinical study as the industry’s most advanced oral small molecule amylin therapy for the treatment of obesity. ACCG-2671 is being evaluated in an ongoing single ascending dose (SAD) study to measure safety, tolerability, pharmacokinetics, and food-effect of single ascending doses in healthy adult participants with data anticipated in 2H 2026. In addition, the Company expects to initiate a multiple ascending dose (MAD) study in Q3 2026.
- In November 2025, the Company declared a second oral small molecule dual amylin calcitonin receptor agonist development candidate, ACCG-3535. ACCG-3535, which is a unique chemical structure compared to ACCG-2671, demonstrated robust food intake suppression and significant, dose-dependent body weight reduction as a monotherapy in diet-induced obese rats. Combination therapy with semaglutide (both concurrently and as a subsequent add-on to semaglutide) resulted in superior weight loss compared to semaglutide or ACCG-3535 monotherapy. The Company expects to initiate a Phase 1 clinical study of ACCG-3535 in Q4 2026.
Multiple presentations at ADA, taking place from June 5–8, 2026
Details of the presentations are as follows:
Title: ACCESS Trial: Dose-Ranging Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with Obesity and Overweight
Session: Oral Presentations - Human Studies in Obesity Treatment: Emerging Therapeutic Options and Strategies for Decision-Making (1032-OR)
Speaker: Julio Rosenstock, MD, University of Texas Southwestern Medical Center
Date: Friday, June 5: 12:45 p.m. – 1:00 p.m. CT
Title: Safety, Tolerability, and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial
Session: General Poster Session (2637-P)
Date: Monday, June 8: 12:30 p.m. – 1:30 p.m. CT
Title: Exploring a Lower Starting Dose of Aleniglipron, an Oral Small Molecule GLP-1RA, to Improve GI Tolerability in Obesity: Beyond the ACCESS Trials
Session: Late Breaking Poster Session (3101-LB)
Date: Sunday, June 7: 12:30 p.m. – 1:30 p.m. CT
Title: Combination Treatment of Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron and Small Molecule Amylin Receptor Agonist ACCG-2671 Demonstrated Additional Weight Loss than Monotreatment in Obese NHPs
Session: Late Breaking Poster Session (3061-LB)
Date: Sunday, June 7: 12:30 p.m. – 1:30 p.m. CT
Title: Comparison of Conditioned Taste Avoidance Profiles between GLP-1 Peptides, Amylin Peptides, and Small Molecule Amylin Receptor Agonists
Session: Late Breaking Poster Session (3062-LB)
Date: Sunday, June 7: 12:30 p.m. – 1:30 p.m. CT
Additional information about the ADA 2026 Scientific Sessions is available at the ADA meeting website (American Diabetes Association).
First Quarter 2026 Financial Highlights
Cash Position: Cash, cash equivalents and short-term investments totaled
Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2026 were
General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2026 were
Net Loss: Net loss for the first quarter of 2026 totaled
About Aleniglipron and Structure Therapeutics’ Oral Metabolic Franchise
Aleniglipron (GSBR-1290) is an investigational orally-available, small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of obesity and T2DM. Through Structure Therapeutics’ structure-based drug discovery platform, aleniglipron was designed to be a biased G Protein-Coupled Receptor (GPCR) agonist, which selectively activates the G-protein signaling pathway. Beyond aleniglipron, Structure Therapeutics is developing next generation oral small molecules including amylin receptor agonists (ACCG-2671 and ACCG-3535), and other combination GLP-1 receptor agonists candidates targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon and apelin receptors.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; the expected timing of ACCESS OLE and Body Composition studies data readouts; the planned initiation of the aleniglipron Phase 3 study and the timing thereof; the expected timing of initial data from the Phase 1 study of ACCG-2671; the planned initiation of the ACCG-3535 Phase 1 study and the timing thereof; the belief that data to date from the ACCESS, ACCESS II, Body Composition, and the ACCESS OLE studies support and inform aleniglipron advancement into Phase 3 clinical development; the Company’s anticipated cash runway and uses of cash; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron; any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials. In addition, when or if used in this press release, the words and phrases "anticipated," "believe," "expect," "potential," "to be," "will," and similar expressions and their variants, as they relate to the Company, may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to topline results that the Company reports are based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; the preliminary nature of the results due to the length of the study and sample size and the results from earlier clinical studies not necessarily being predictive of future results; potential delays in the commencement, enrollment and completion of the Company's planned Phase 3 clinical program and other clinical studies; disruptions to the operations of the FDA or other U.S. governmental agencies or comparable foreign regulatory authorities caused by funding shortages, leadership changes, or staffing reductions; the Company's ability to advance aleniglipron, ACCG-2671, LTSE-2578, ACCG-3535, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company's therapeutic candidates; competitive products or approaches limiting the commercial value of the Company's product candidates; the timing and results of preclinical and clinical studies; the Company's ability to fund development activities and achieve development goals; the Company's reliance on third parties, including clinical research organizations, manufacturers, suppliers and collaborators, over which it may not always have full control; general geopolitical and macroeconomic conditions, including as a result of tariffs and various global conflicts; the Company's ability to protect its intellectual property; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
Jun Yoon
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
| STRUCTURE THERAPEUTICS INC. | ||||||||
| Condensed Consolidated Statements of Operations | ||||||||
| (unaudited) | ||||||||
| (In thousands) | ||||||||
| THREE MONTHS ENDED | ||||||||
| MARCH 31, | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 66,507 | $ | 42,867 | ||||
| General and administrative | 22,872 | 13,444 | ||||||
| Total operating expenses | 89,379 | 56,311 | ||||||
| Loss from operations | (89,379 | ) | (56,311 | ) | ||||
| Interest and other income, net | 13,601 | 9,576 | ||||||
| Loss before provision for income taxes | (75,778 | ) | (46,735 | ) | ||||
| Provision for (benefit from) income taxes | 190 | 98 | ||||||
| Net loss | $ | (75,968 | ) | $ | (46,833 | ) | ||
| Research and development | $ | 5,101 | $ | 2,699 | ||||
| General and administrative | 6,538 | 3,219 | ||||||
| Total share-based compensation | $ | 11,639 | $ | 5,918 | ||||
| STRUCTURE THERAPEUTICS INC. | |||||||
| Condensed Consolidated Balance Sheet Data | |||||||
| (unaudited) | |||||||
| (In thousands) | |||||||
| MARCH 31, | DECEMBER 31, | ||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash, cash equivalents and short-term investments | $ | 1,458,504 | $ | 1,446,197 | |||
| Prepaid expenses and other current assets | 32,094 | 124,106 | |||||
| Total current assets | 1,490,598 | 1,570,303 | |||||
| Property and equipment, net | 6,365 | 6,653 | |||||
| Operating right-of-use assets | 5,606 | 6,245 | |||||
| Other non-current assets | 5,555 | 717 | |||||
| Total assets | $ | 1,508,124 | $ | 1,583,918 | |||
| Liabilities and shareholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 7,822 | $ | 13,864 | |||
| Accrued expenses and other current liabilities | 46,553 | 46,543 | |||||
| Operating lease liabilities, current portion | 2,609 | 2,878 | |||||
| Total current liabilities | 56,984 | 63,285 | |||||
| Operating lease liabilities, net of current portion | 3,183 | 3,609 | |||||
| Other non-current liabilities | 863 | 647 | |||||
| Total liabilities | 61,030 | 67,541 | |||||
| Total shareholders’ equity | 1,447,094 | 1,516,377 | |||||
| Total liabilities and shareholders’ equity | $ | 1,508,124 | $ | 1,583,918 | |||
